Retifanlimab Demonstrated Antitumor Activity in MSI-H/dMMR Endometrial Cancer
The PD-1 inhibitor retifanlimab showed antitumor activity with a tolerable safety profile among patients with MSI-H/dMMR endometrial cancer.
The PD-1 inhibitor retifanlimab showed antitumor activity with a tolerable safety profile among patients with MSI-H/dMMR endometrial cancer.
Does abemaciclib and letrozole effective slow or stop endometrial cancer cell growth?
All patients will receive mirvetuximab soravtansine and pembrolizumab in this study.
A phase 3 study seeks to evaluate the value of selecting therapy based on molecular profiling.
Patients with advanced or recurrent endometrial cancer enrolled in the experimental arm will receive atezolizumab in combination with paclitaxel and carboplatin.
Palbociclib plus letrozole prolonged PFS and maintained QoL compared with placebo plus letrozole, according to results from a phase 2 trial.
Researchers identified factors for increased risk of clinically significant fatigue among women who underwent surgery for gynecologic cancers.
The trajectory of follow-up care for women undergoing a failed endometrial biopsy has been largely unexplored.
Clinicians may be underappreciating the extent of adverse events in women with cervical and endometrial cancer who undergo radiotherapy.
Molecular subtypes, as indicated by the ProMisE classifier, of endometrial clear cell carcinoma are associated with different prognoses.